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Abstract: Low-density lipoprotein-cholesterol (LDL-C) is a well established coronary heart disease 
(CHD) risk factor. However, the ability of this metabolic risk factor alone to identify individuals at risk 
for future CHD events is limited. The raised triglycerides-low high-density lipoprotein-cholesterol 
(HDL-C) dyslipidemia was shown to be an important cardiovascular risk factor independently of 
LDL-C levels. Fibric acid derivatives (ﬁ  brates) have been used in clinical practice for more than 
2 decades as a class of agents known to decrease triglyceride levels while substantially increasing 
HDL-C levels. Through peroxisome proliferator-activated α-receptors, ﬁ  brates have a signiﬁ  cant 
impact on the synthesis of several apolipoproteins and enzymes of lipoprotein metabolism as well 
as on the expression of several genes involved in ﬁ  brinolysis and inﬂ  ammation. Data from recent 
primary and secondary prevention clinical trials demonstrate the efﬁ  cacy of ﬁ  brate therapy in 
patients with the raised triglycerides-low HDL-C dyslipidemia. This review summarizes current 
data regarding mechanism of action and the metbolic effects of ﬁ  brates, as well as results from major 
clinical trials on the efﬁ  cacy of this mode of lipid lowering therapy. In addition, recent data from 
subgroup analyses of the Bezaﬁ  brate Infarction Prevention trial, demonstrating several important 
metabolic and long-term cardiovascular effects of bezaﬁ  brate therapy, are detailed.
Keywords: ﬁ  brates, high-density lipoprotein-cholsterol, metabolic syndrome, peroxisome 
proliferator-activated α-receptors, cardiac events
Introduction
Considerable progress in the understanding of coronary heart disease (CHD) risk 
factors has been made in the past decades, leading to the development of strategies 
to reduce CHD event rate. The ability of HMG-CoA reductase inhibitors (statins) to 
reduce the occurrence of CHD in individuals with hypercholesterolaemia has been 
reported in large primary and secondary prevention trials. Intervention trials using 
statins to lower low-density lipoprotein cholesterol (LDL-C) have consistently shown 
substantial reductions in major cardiovascular events in the treated groups (Shepard 
et al 1995; Sacks et al 1996; Downs et al 1998; Sever et al 2003; Baigent et al 2005), 
that was shown to be a function of the extent of LDL-C lowering (Baigent et al 2005). 
However, risk reduction with statin therapy is limited to about 30%, and the ability 
to adequately identify individuals at high risk for the development of CHD by total 
or LDL-C levels is limited by the fact that almost 50% of CHD patients have serum 
cholesterol levels in the normal range (Genest et al 1992). Thus, additional factors 
appear to modulate the risk of CHD independently LDL-C level.
Early data had shown that low high-density lipoprotein cholesterol (HDL-C) levels are 
inversely related to CHD incidence in both men and women (Yaari et al 1981; Gordon et al 
1997). It has also been demonstrated that the risk associated with HDL-C is independent 
of LDL-C levels (Castelli et al 1987). Furthermore, a recent post hoc analysis from the 
Treating to New Targets (TNT) study (Barter et al 2007), has shown that HDL-C levels 
are predictive of major cardiovascular events even in patients who maintain LDL-C levels Vascular Health and Risk Management 2008:4(1) 132
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below 70 mg/dL while on statin therapy. In the majority of 
patients with low HDL-C who develop CHD, this lipoprotein 
alteration is most often accompanied by elevated triglyceride 
levels (Manninem et al 1992; Jeppesen et al 1997; Gotto 
et al 1998). This raised triglycerides-low HDL-cholesterol 
dyslipidemic state is a common feature of the altered risk proﬁ  le 
of patients with type 2 diabetes, and is largely the consequence 
of an insulin-resistant state found in viscerally obese patients 
with the metabolic syndrome (Howard et al 1987; Laakso 
et al 1990; Bieman et al 1992). Thus, even in the absence of 
hyperglycemia or of type 2 diabetes, overweight/obese patients 
with the features of the metabolic syndrome and the raised 
triglycerides-low HDL-cholesterol dyslipidemic state have a 
substantially increased risk of CHD, despite LDL-C levels 
that are presumably within the ‘normal’ range (Lammarch et al 
1998). Such dyslipidemia is also characterized by increased 
levels of atherogenic lipoproteins including, elevated apo B, and 
small, dense LDL and HDL particles (Tchernof et al 1996).
It had been known for decades that treatment with ﬁ  brates 
results in substantial decreases in triglyceride levels associated 
with a moderate increase in HDL-C levels and usually a small 
reduction in LDL-C levels. This class of drugs has been par-
ticularly useful in patients with primary hypertriglyceridemia, 
mixed hyperlipidemia, and in patients with type 2 diabetes and 
the raised triglycerides-low HDL-C dyslipidemia (Fruchart 
et al 1998). In recent years, signiﬁ  cant progress has been made 
in understanding the mode of action of ﬁ  brates. These data 
have shown that ﬁ  brates activate speciﬁ  c transcription fac-
tors belonging to the nuclear hormone receptor superfamily, 
termed peroxisome proliferator-activated receptors (PPAR). 
Activation of these receptors alters the transcription rate of 
target genes which play a key role in the development of 
atherosclerosis. Recent data from the Veterans Affairs High-
Density Lipoprotein Cholesterol Intervention Trial ([VA-HIT] 
Rubins et al 1999), and subgroup analyses from the Bezaﬁ  -
brate Infarction Prevention trial ([BIP] The BIP Study Group 
2000) have demonstrated that ﬁ  brate therapy improves both 
insulin sensitivity and the blood lipid proﬁ  le, and signiﬁ  cantly 
attenuates the risk of long-term major cardiovascular events 
(Tennenbaum et al 2005; Goldenberg et al 2006; Goldenberg 
et al 2007). In this review, the pharmacology of the ﬁ  brates is 
discussed, together with data from recent clinical trials that 
indicate the potential of the ﬁ  brates in general, and bezaﬁ  -
brate speciﬁ  cally, in managing dyslipidemia, with a focus 
on the use of these drugs in the atherogenic dyslipidemia 
commonly observed in obese, insulin-resistant and diabetic 
individuals.
Mechanism of action
Fibrates act as synthetic ligands for PPARα, which are mainly 
located in the liver, skeletal muscle, heart muscle, and cells in 
the arterial wall that play a key role in the development of athero-
sclerosis (Vamecq et al 1999; Tennenbaum et al 2003; Berger 
et al 2005). PPAR bind as heterodimers with another nuclear 
receptor, the retinoid X receptor, to speciﬁ  c response elements 
termed peroxisome proliferator response elements and alter the 
transcription rate of target genes. A summary of PPARα-medi-
ated gene regulation by ﬁ  brates is provided in Table 1.
Effect on plasma lipids and lipoproteins
Fibrates reduce plasma levels of triglycerides by 30%–50% 
and typically increase levels of HDL-C by 5%–15%, depend-
ing on lipid phenotype and baseline concentration. Fibrates 
may also reduce LDL-C by up to 15%–20% although 
the effect is variable, depending on the underlying lipid 
abnormality and baseline lipid phenotype (Chapman et al 
Table 1 PPARα-mediated gene regulation by ﬁ  brates
Target gene  Function of gene product  Gene expression
Lipoprotein lipase  Lipolysis, clearance of triglyceride-rich lipoproteins  Increase
Apolipoprotein CIII Inhibits  VLDL  clearance  Decrease
Apolipoprotein AI  HDL-C formation, reverse cholesterol transport  Increase
Apolipoprotein AII  HDL-C formation, reverse cholesterol transport  Increase
Acyl CoA synthetase  Fatty acid activation, acyl CoA esters  Increase
ABCA1  HDL-C formation, cellular cholesterol efﬂ  ux  Increase
Fatty acid binding protein  Cellular fatty acid uptake  Increase
b-oxidation pathway  Fatty acid oxidation  Increase
Acetyl CoA carboxylase  Fatty acid synthesis  Decrease
Fibrinogen Blood  clotting  Decrease
C-reactive protein  Acute phase reactant  Decrease
Interleukin 6  Acute phase reactant  Decrease
Cyclooxygenase-2  Fatty acid metabolism  Decrease
VCAM-1 Adhesion  molecule  Decrease
Abbreviations: ABCA, ATP binding cassette transporter A1; VCAM-1, vascular cell adhesion molecule-1.Vascular Health and Risk Management 2008:4(1) 133
Fibrate therapy
2006). Recent investigations have revealed that the lipid 
effects of ﬁ  brates are mediated, at least partly, through the 
transcription of genes encoding for proteins that control 
lipoprotein metabolism (Figure 1 and Table 1). Activation of 
PPARα results in increased lipolysis and plasma clearance of 
atherogenic triglyceride-rich lipoproteins via the activation 
of lipoprotein lipase and ApoAV and reduced production 
of the lipoprotein lipase inhibitor ApoCIII (Haubenwallner 
et al 1995; Staels et al 1995a; Stael et al 1998; Chapman et al 
2006). Fibrate therapy also promotes the β-oxidation of fatty 
acids, thus reducing the availability of free fatty acids for 
triglyceride synthesis (Schoonjans et al 1996). In addition, 
de novo fatty acid synthesis is inhibited through reductions 
in acetyl-CoA carboxylase and fatty acid synthase activity; 
thereby reducing the availability of fatty acids for triglyceride 
synthesis (Schoonjans et al 1996a; Schoonjans et al 1996b).
PPARα activation also increases ApoAI and ApoAII 
synthesis (the major proteins in HDL) (Schoonjans et al 
1996a; Schoonjans et al 1996b). Cholesteryl ester transfer 
protein (CETP) activity was found to be reduced with 
ﬁ  brate therapy (Kiyanagi et al 2006); and the reduction 
in CETP-mediated transfer of lipid from HDL-C to very 
(V) LDL may also contribute to the observed increase in 
HDL-C levels.
Effects on LDL and HDL particle 
subclasses
Evidence suggests that LDL particle subclasses may differ in 
atherogenicity, with small, dense LDL associated with greater 
CHD risk than large, buoyant LDL. The larger particles have a 
high binding afﬁ  nity for cellular LDL receptors, and are less 
susceptible to oxidation. Individuals with the metabolic syn-
drome and the raised triglycerides-low HDL-C dyslipidemia 
characteristically have LDL particles that are smaller and 
contain less cholesterol than average (Berneis et al 2002). As 
a result, the number of atherogenic LDL particles is frequently 
Figure 1 Mechanism of action of ﬁ  brates.
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; PPARα, peroxisome proliferator-activated receptor-α; PPRE, peroxisome proliferator response 
elements; RXR, retinoid X receptor; ↑ indicates increase; ↓ indicates decrease.Vascular Health and Risk Management 2008:4(1) 134
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elevated in this population, even though LDL-C levels are not. 
Cardiovascular risk was found to be better explained by con-
centrations of LDL particles or plasma levels of apolipopro-
tein B (ApoB), than by LDL-C (Berneis et al 2002; Blake et al 
2002; Rizzo et al 2007). Fibrate therapy was shown to alter 
LDL subclass distribution among normolipemic subjects with 
predominantly dense LDL-C (Superko et al 2005), resulting 
in a reduction in small dense LDL and an opposite effect on 
HDL subclass distribution (Guérin et al 1996). In a substudy 
of VA-HIT (Otvos et al 2006), treatment with gemﬁ  brozil was 
associated with an increase LDL size and a reduction in the 
number of LDL particles by 5%, while raising the number 
of HDL particles by approximately 10% and of small HDL 
subclass particles by 21%. Furthermore, concentrations of 
these LDL and HDL particles achieved with gemﬁ  brozil were 
shown to be signiﬁ  cant, independent, predictors of major 
cardiac events and helped explain the demonstrated beneﬁ  t of 
ﬁ  brate therapy in this population. Other studies have shown 
that treatment with fenoﬁ  brate, ciproﬁ  brate, and bezaﬁ  brate 
also exert a beneﬁ  cial effect on LDL subclass distribution. 
Notably, among the different agents, fenoﬁ  brate has been 
found to be particularly effective in modulating LDL size and 
subclasses (Rizzo et al 2007).
Non-lipid effects
Fibrates were shown to exert pleiotropic effects in the 
artery wall. PPARα is involved in the control of the anti-
inﬂ  ammatory response, via inhibition of the transcription 
factor NFκB (Chapman 2003), and to attenuate the production 
of pro-inﬂ  ammatory stimuli such as interleukin 6 and various 
prostaglandins, as well as the acute phase proteins, including 
ﬁ  brinogen and C-reactive protein (Devchand et al 1996; 
Staels et al 1998).
Fibrates have favorable effects on coagulation and ﬁ  bri-
nolysis. Bezaﬁ  brate was shown to reduce levels of ﬁ  brinogen 
by up to 20% (Schonfeld et al 1994), and ciproﬁ  brate and 
fenoﬁ  brate have been shown to increase ﬁ  brinolysis and 
attenuate platelet hyperaggregability in hypercholesterolemic 
subjects (Simpson et al 1998).
Adverse effects and precautions
Common adverse reactions of fibrate therapy include 
gastrointestinal (epigastric distress, flatulence, nausea, 
diarrhea, constipation) and dermatologic (pruritus, urticaria, 
or erythema) symptoms, whereas reactions related to the 
musculoskeletal (muscular weakness, pain, and muscle 
cramps) and neurological (headache, dizziness) systems are 
less common. Several speciﬁ  c precautions are listed below.
Hematologic changes
Mild hemoglobin, leukocyte and platelet decreases have 
occurred occasionally following initiation of bezaﬁ  brate 
therapy. However, these levels stabilize during long-term 
administration. Periodic blood counts are recommended 
during the ﬁ  rst 12 months of administration.
Liver function
Abnormal liver function tests have been observed occa-
sionally during ﬁ  brate administration, including elevated 
transaminases, and decreased or, rarely, increased alkaline 
phosphatase. However, these abnormalities are reversible 
upon discontinuation of the drug. Therefore, periodic liver 
function tests (AST, ALT, and GGT [if originally elevated]) 
in addition to other baseline tests are recommended after 
3–6 months and at least yearly thereafter. Fibrate therapy 
should be terminated if drug-related abnormalities persist.
Cholelithiasis
Fibrates may increase cholesterol excretion into the bile, and 
may lead to cholelithiasis. If such is suspected, gallbladder 
studies are indicated. Fibrate therapy should be discontinued 
if gallstones are found.
Hepatobiliary disease
In patients with a past history of jaundice or hepatic disorder, 
ﬁ  brates should be used with caution.
Skeletal muscle
Treatment with drugs of the ﬁ  brate class has been associated 
on rare occasions with myositis or rhabdomyolysis, usually 
in patients with impaired renal function. Myopathy should 
be considered in any patient with diffuse myalgias, muscle 
tenderness/weakness, or marked elevations in creatinine 
phosphokinase (CPK) levels. Patients should be advised 
to report unexplained muscle pain, tenderness or weakness 
promptly, particularly if accompanied by malaise or fever. 
Levels of CPK should be assessed in patients reporting these 
symptoms, and ﬁ  brate therapy should be discontinued if 
markedly elevated CPK levels (10 times the upper limit of 
normal) occur or myopathy is diagnosed.
Children
Limited experience is available in children. Therefore, in the 
absence of adequate information concerning the long-term 
safety, ﬁ  brates should be used with caution in treating this 
population.Vascular Health and Risk Management 2008:4(1) 135
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Pregnancy and lactation
Strict birth control procedures must be exercised by 
women of childbearing potential. If pregnancy occurs 
despite birth control procedures, ﬁ  brate therapy should 
be discontinued. Women planning a pregnancy should 
discontinue ﬁ  brate therapy several months prior to con-
ception. In the absence of data concerning the presence 
of ﬁ  brates in human breast milk, the drugs should not be 
used by nursing mothers.
Clinical trials
Fibrates have been in clinical use for over 30 years. Cloﬁ  brate 
was introduced in the 1970s and was followed by gemﬁ  brozil, 
bezaﬁ  brate, fenoﬁ  brate and ciproﬁ  brate. Although there have 
been fewer intervention studies with ﬁ  brates than with statins, 
the majority of available evidence indicate long-term beneﬁ  -
cial effects in high-risk patients with the raised triglycerides-
low HDL-C dyslipidemia of the metabolic syndrome, both 
in primary and secondary intervention settings. A summary 
of data from major randomized trials of ﬁ  brate therapy is 
provided in Table 2.
Primary prevention
Cloﬁ  brate and gemﬁ  brozil have been investigated in a primary 
prevention setting in the general population (Table 2). In the 
WHO Cloﬁ  brate Study (Committee of Principal Investigators 
1978), 10,627 men without CHD treated with cloﬁ  brate for 5 
years showed a 25% reduction in myocardial infarction (MI) 
and a 20% reduction in ﬁ  rst major coronary event. These ben-
eﬁ  cial results were, however, overshadowed by the reported 
increase in mortality from non-cardiovascular disease, par-
ticularly cancer (Committee of Principal Investigators 1978), 
although subsequent follow-up showed a smaller difference 
in cancer incidence between the cloﬁ  brate and control groups 
(Committee of Principal Investigators 1978).
The Helsinki Heart Study (Frick et al 1987) was a 
placebo-controlled study, including more than 4,000 men 
at moderate risk of CHD with a range of lipid patterns, but 
generally with an elevated LDL-C level. The study showed 
that treatment with gemﬁ  brozil (1,200 mg/day), resulted in 
an 11% decrease in LDL-C, a 35% decrease in triglycerides 
and an 11% increase in HDL-C, compared with placebo. 
These lipid changes were associated with a 34% reduction 
Table 2 Summary of major randomized intervention trials involving ﬁ  brate therapy
Trial  Drug  No. of   Baseline lipids mg/dL  End point  Outcome
   patients  TC  TG  HDL-C
       
Primary prevention
WHO Cloﬁ  brate  10627  248  NR  NR  Nonfatal MI  25% reduction
             (p    0.05)
Helsinki Heart  Gemﬁ  brozil  4081  270  176  47  Nonfatal MI/CHD  34% reduction
Study           death  (p    0.05)
Secondary prevention
Newcastle   Cloﬁ  brate  497  246  NR  NR  Fatal/nonfatal MI  14% reduction
             (p    0.10)
Edinburgh   Cloﬁ  brate  717  265  NR  NR  CHD events  53% reduction
             (p    0.05)
CDP Cloﬁ  brate  3892  250  NR  NR  Nonfatal MI/CHD  8% reduction 
           death  (p    0.10)
Stockholm Ischaemic  Cloﬁ  brate  555  249  209  48  Total death  26% reduction
Heart Disease               (p   0.05)
VA-HIT   Gemﬁ  brozil  2531  175  161  32  Nonfatal MI/CHD  22% reduction
           death  (p    0.05)
BIP   Bezaﬁ  brate  3090  212  145  35  Fatal/nonfatal MI/sudden  9% reduction
           death  (p    0.10)
Leader Bezaﬁ  brate  1568  216  189  43  Nonfatal MI/CHD  4% reduction
           death/stroke  (p    0.10)
Primary/secondary
prevention
FIELD Fenoﬁ  brate  2795  195  119  42  Nonfatal MI/CHD  11% reduction
           death  (p    0.10)
Notes: See text for abbreviations of study names.
Abbreviations: CHD, coronary heart disease; MI, myocardial infarction; NR, not reported.Vascular Health and Risk Management 2008:4(1) 136
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in major coronary events at ﬁ  ve years (p   0.02), as well as 
a 37% reduction in non-fatal MI (p   0.05). No signiﬁ  cant 
difference in overall mortality was observed between the 
two groups.
Secondary prevention
The value of ﬁ  brate therapy in the secondary prevention set-
ting is supported by numerous studies (Table 2). Two small 
trials of cloﬁ  brate therapy, Newcastle (Trial of cloﬁ  brate in 
the treatment of ischemic heart disease 1971) and Edinburgh 
(Trial of cloﬁ  brate in the treatment of ischemic heart disease), 
failed to ﬁ  nd a signiﬁ  cant reduction in CHD deaths, but did 
ﬁ  nd that cloﬁ  brate prevented nonfatal-MI to a variable extent. 
The Coronary Drug Project (CDP) (Cloﬁ  brate and niacin in 
coronary heart disease 1975) was a larger secondary preven-
tion trial that showed a non-signiﬁ  cant reduction in CHD 
events with cloﬁ  brate therapy. However, a late lipid-lowering 
therapy effect was observed in an extended follow-up of 
the trial (Canner et al 1986), nine years after termination 
of the trial. The authors attributed this to the transformation 
of an early favorable effect of niacin in decreasing nonfatal 
reinfarction, into a mortality beneﬁ  t over subsequent years. 
In the Stockholm Ischaemic Heart Disease Secondary Pre-
vention Study (Carlson et al 1988), combination treatment 
with cloﬁ  brate (2 g/day) and nicotinic acid (3 g/day) was 
investigated in 555 post-MI patients (279 received active 
treatment). Compared with a control group, active treatment 
reduced triglycerides by 19% and signiﬁ  cantly reduced total 
and CHD mortality by 26% (p   0.05) and 36% (p   0.01), 
respectively. Notably, CHD risk reduction was only evident 
in patients with triglyceride levels higher than the median 
value at baseline; subjects in whom triglyceride levels were 
reduced by more than 30% (over 40% of treated patients) 
experienced a 60% reduction in CHD mortality (p   0.01). 
Subsequently, VA-HIT (Rubins et al 1999), involving 2,531 
men with established CHD, acceptable LDL-C levels, low 
HDL-C, and elevated triglycerides (Table 2), showed that 
treatment with gemfibrozil produced a significant 22% 
reduction in the risk of the primary end point of CHD death 
or non-fatal MI, as well as CHD mortality. It is noteworthy 
that 25% of patients enrolled in VA-HIT had diagnosed dia-
betes and over 50% of patients had features of the metabolic 
syndrome. The BIP study (The BIP Study Group 2000; also 
described separately in the following section) comprised 
3090 patients allocated to bezaﬁ  brate (400 mg/day) or pla-
cebo. A signiﬁ  cant reduction in plasma triglyceride levels and 
an increase in HDL-C were observed in this study although 
there was no signiﬁ  cant difference in the ﬁ  ve-year coronary 
event rate compared with placebo (9.4% reduction, p = 0.26). 
However, bezaﬁ  brate was shown to be particularly beneﬁ  cial 
among patients with elevated triglycerides ( 200 mg/dL) at 
baseline, in whom a 40% reduction in coronary risk at ﬁ  ve 
years was observed. The Lower Extremity Arterial Disease 
Event Reduction (LEADER) trial (Meade et al 2002) enrolled 
1568 elderly men with lower extremity arterial disease, 
and showed that bezaﬁ  brate (400 mg/day) produced a 40% 
reduction in non-fatal coronary events (p = 0.05), although 
there was no signiﬁ  cant reduction in the combined end point 
of CHD and stroke.
Angiographic studies have demonstrated the beneﬁ  cial 
effect of ﬁ  brate therapy on atherosclerosis progression. The 
Bezaﬁ  brate Coronary Atherosclerosis Intervention Trial 
([BECAIT] Ericsson et al 1996), was a relatively small 
trial designed to evaluate the effects of treatment with 
bezaﬁ  brate on angiographic disease in 92 young male MI 
survivors. The study showed a signiﬁ  cant reduction in the 
progression of coronary atherosclerosis, as assessed by the 
change in minimum lumen diameter, in patients treated with 
bezaﬁ  brate compared with placebo. In the Lopid Coronary 
Angiography Trial (Frick et al 1997), 395 men with low 
HDL-C and LDL-C levels who had previously undergone 
CABG, were treated with gemﬁ  brozil (1200 mg/day). The 
study medication was associated with signiﬁ  cantly decreased 
progression of coronary artery disease in native coronary 
segments compared with placebo.
Type 2 diabetes
The pharmacological proﬁ  le of the ﬁ  brates, described above, 
suggests that these agents may prove useful in correcting the 
atherogenic dyslipidemia typically associated with type 2 
diabetes and the metabolic syndrome.
Subgroup analyses of data from the Helsinki Heart Study 
(Koskinen et al 1992) and VA-HIT (Rubins et al 2002) 
showed that among patients with type 2 diabetes, treatment 
with gemﬁ  brozil was associated with a signiﬁ  cant reduction 
in the risk of coronary events that ranged from 68% (Koskinen 
et al 1992) in the primary intervention setting to 32% (Rubins 
et al 2002) in the secondary prevention setting. In the St. 
Mary’s, Ealing, Northwick Park Diabetes Cardiovascular 
Prevention (SENDCAP) study (Elkeles et al 1998), 164 type 
2 diabetes patients without a history of CHD, treated with 
bezaﬁ  brate (400 mg/day) for three years, had a lower CHD 
event rate compared with placebo (7% vs. 23%, p = 0.01). 
There was, however, no difference between the groups in 
progression of carotid and femoral artery atherosclerosis, as 
assessed by changes in intima-media thickness.Vascular Health and Risk Management 2008:4(1) 137
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More recently, the Diabetes Atherosclerosis Intervention 
Study ([DAIS] Vakkilainen et al 2003), involving 418 
patients with type 2 diabetes has provided clear evidence of 
the value of ﬁ  brate therapy in diabetic patients. Treatment 
with micronised fenoﬁ  brate, at a dose of 200 mg/day for at 
least 3 years, was associated with a 40% reduction in angio-
graphic progression of coronary artery disease, as well as a 
23% reduction in the cardiovascular event rate, compared 
with placebo. These beneﬁ  cial effects were associated with 
reduction in the levels of triglycerides (by 29%) and LDL-C 
(by 5%), and an increase in HDL-C (by 7%) and LDL particle 
size (Vakkilainen et al 2003).
The Fenoﬁ  brate Intervention and Event Lowering in 
Diabetes (FIELD) study (The FIELD study investigators 
2005) evaluated the role of ﬁ  brate therapy in preventing 
cardiovascular events in patients with type 2 diabetes, con-
sidered at increased risk for CHD. After a mean follow-up 
of 5 years, therapy with fenoﬁ  brate was associated wuth a 
non-signiﬁ  cant 11% reduction in the primary end point of 
nonfatal MI or CHD death. However, total cardiovascular 
events, corresponding to the secondary end point, were 
signiﬁ  cantly reduced with fenoﬁ  brate by 11% (p = 0.035), 
mainly due to signiﬁ  cant reductions in non-fatal MI (by 
24%, p = 0.01) and coronary revascularization (by 21%, 
p = 0.003). Treatment effects were larger in patients with-
out cardiovascular disease than in those with a history of 
cardiovascular disease. Notably, end points that concerned 
microangiographic manifestations of diabetes were signiﬁ  -
cantly improved by fenoﬁ  brate treatment; these included a 
reduction in the need for laser treatment for retinopathy and 
reduction in the progression of albuminuria.
Bezaﬁ  brate therapy: recent data 
from the BIP trial
Bezaﬁ  brate was the ﬁ  rst clinically tested pan – (alpha, 
beta/delta, gamma) PPAR activator (Peters et al 2000; The 
BIP Study Group 2000; Cobrero et al 2001; Poirier 2001; 
Vazquez 2001), and is a sole pan PPAR activator with more 
than a quarter of a century of a therapeutic experience with 
a good safety proﬁ  le. The BIP study was designed to deter-
mine whether bezaﬁ  brate would reduce CHD mortality and 
nonfatal MI in CHD patients with low HDL-C and LDL-C 
in a moderate range (The BIP Study Group 2000). The study 
demonstrated fewer cardiac events with bezaﬁ  brate (13.6%) 
as compared with placebo (15.0%) during a 6.2-year mean 
follow-up period. However, event rate was not signiﬁ  cantly 
reduced (p = 0.26) despite reductions of 5% in LDL-C, 16% 
in triglyceride, and 10% in ﬁ  brinogen levels, together with 
an increase of 14% in HDL-C levels compared with placebo. 
A post hoc analysis in patients with high baseline triglycer-
ides (200 mg/dL) revealed that the reduction in the cumula-
tive probability of the primary end point by bezaﬁ  brate was 
39.5% (p = 0.02) in that subgroup.
There are several explanations for the differences in out-
come between VA-HIT and BIP in addition to the difference 
in the type of ﬁ  brate drug. First, LDL-C levels in BIP were in 
a moderately high range at baseline (averaging 149 mg/dL), 
necessitating a relatively large prescription rate of “off-trial” 
lipid lowering therapies, mainly in the placebo group (15% 
of placebo-allocated patients received active lipid therapy 
by the end of the study), thereby attenuating the margin of 
difference in outcome between the placebo and active treat-
ment groups. Second, differences in patient characteristics 
might have affected outcome in the 2 trials: BIP excluded 
individuals with diabetes and higher levels of blood glucose 
as well as recruited fewer individuals with components of 
the metabolic syndrome, in whom the efﬁ  cacy of ﬁ  brate 
therapy is enhanced, resulting in a lower event rate during 
follow-up. Despite these differences in trial design, recent 
subgroup analyses from BIP revealed several important 
ﬁ  ndings regarding the long-term cardiovascular effects of 
bezaﬁ  brate that are described below.
Relationship between on-treatment 
increments in serum HDL-cholesterol 
levels and cardiac mortality
In a subanalysis of BIP we evaluated the relationship 
between changes in serum levels of HDL-C under bezaﬁ  -
brate therapy and cardiac mortality in enrolled subjects 
(Goldenberg et al 2006). Long-term follow-up revealed that 
cardiac mortality was signiﬁ  cantly reduced with increasing 
increments of on-treatment HDL-C change (9.5%, 6.6%, 
and 6.3% of patients died of cardiac causes in tertiles 1, 2, 
and 3 of HDL-C increase, respectively [p for trend = 0.02]); 
Figure 2). The magnitude of on-treatment HDL-C increment 
in the trial was shown to be independently associated with 
reduced risk of cardiac death: patients who did not respond 
to bezaﬁ  brate therapy by increasing serum HDL-C levels 
(tertile 1 HDL-C change) did not experience a survival 
beneﬁ  t with bezaﬁ  brate therapy (hazard ratio: 1.05 [95% CI 
0.74–1.47]), whereas responders (tertile 3 HDL-C increase) 
experienced a signiﬁ  cant 35% reduction in the risk of cardiac 
death with bezaﬁ  brate (HR = 0.65 [95% CI 0.43–0.97]). 
Furthermore, the risk of cardiac mortality was reduced by 
27% for every 5 mg/dL increase in on-treatment HDL-C 
change (p   0.001). Thus, these ﬁ  ndings demonstrate an Vascular Health and Risk Management 2008:4(1) 138
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Figure 2 All-cause and cardiac mortality rates in tertiles of HDL-C change in the bezaﬁ  brate group compared to the placebo group.
*p for trend   0.05
Reprinted with permission from Goldenberg et al (2006).
independent association between a rise in HDL-C with 
bezaﬁ  brate therapy and a reduction in cardiac mortality, and 
suggest that monitoring short-term response to bezaﬁ  brate 
therapy through HDL-C change may indicate the potential 
long-term beneﬁ  t of the drug.
Long-term cardioprotective effects 
of bezaﬁ  brate therapy
We have recently completed an evaluation of the effect of 
bezaﬁ  brate therapy over an extended follow-up period of 
BIP (Goldenberg et al 2007). After discontinuation of study 
medication, patients were observed for coronary events for 
an additional period, bringing the total follow-up time in the 
current analysis to a mean of 8.2 years (median: 7.9 years; 
interquartile range: 7.2–8.7 years). Our data demonstrate 
that during long-term follow-up bezaﬁ  brate therapy was 
associated with a signiﬁ  cant 17% reduction (p = 0.03) in 
the combined end point of cardiac death or nonfatal MI 
(Figure 3). Using interaction-term analysis, we have also 
shown that the beneﬁ  t of bezaﬁ  brate therapy was pronounced 
(18% risk reduction; p = 0.03) without- or before- treatment 
with off-trial lipid lowering therapies was initiated dur-
ing follow-up, and attenuated (HR = 1.05; p = 0.85) after 
therapy with off-trial lipid lowering therapies was initiated 
during the observation period. These new data suggest that 
bezaﬁ  brate therapy is associated with signiﬁ  cant long-term 
cardiovascular protection that may extend beyond the period 
of active drug therapy.
Effect of bezaﬁ  brate therapy in patients 
with the metabolic syndrome
A post hoc analysis of BIP evaluated the effect of bezaﬁ  -
brate on the incidence of MI during long-term follow-up in 
enrolled patients with metabolic syndrome (Tenenbaum et al 
2005). Patients who displayed at least 3 of the following 5 
risk factors were considered to have metabolic syndrome: 
(1) a fasting glucose level of 110 mg/dL (6.11 mmol/L); 
(2) a triglyceride level of 150 mg/dL (1.70 mmol/L); 
(3) HDL-C level less than 40 mg/dL in men or less than 
50 mg/dL in women; (4) a systolic blood pressure of 130 
mm Hg or diastolic blood pressure of 85 mm Hg; and (5) 
a body mass index of 28.0 kg/m2. During the course of the 
extended follow-up period bezaﬁ  brate was associated with a 
signiﬁ  cant reduction in the risk of MI, and of the combined 
primary endpoint of BIP, which consisted of nonfatal MI 
or sudden cardiac death, among patients with at least 3 risk Vascular Health and Risk Management 2008:4(1) 139
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Figure 4 Outcome of patients with the metabolic syndrome in BIP.
*p   0.05.
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Figure 3 Kaplan-Meier cumulative probability of outcome the combined endpoint of 
cardiac death or nonfatal myocardial infarction, and cardiac death separately, during 
an extended follow-up of the BIP trial.











factors for the metabolic syndrome (Figure 4). Furthermore, 
the beneﬁ  t of bezaﬁ  brate therapy was shown to be enhanced 
in patients with augmented features (at least 4 risk factors) of 
the metabolic syndrome (56% reduction of cardiac mortality 
during 8-year follow-up), whereas the beneﬁ  t of bezaﬁ  brate 
was attenuated in patients without features of the metabolic 
syndrome.
Bezaﬁ  brate therapy for the prevention 
of type 2 diabetes mellitus in patients 
with coronary artery disease
In a recent study from BIP we evaluated whether pharmaco-
logical intervention with bezaﬁ  brate that inﬂ  uences primary 
lipid metabolism can also delay development of type 2 
diabetes (Tenenbaum et al 2004). The study comprised 303 
non-diabetic study patients with a fasting blood glucose level 
of 110 to 125 mg/dL, who were allocated to either 400 mg 
bezaﬁ  brate (n = 156) or placebo (n = 147 patients) once a 
day. During follow-up, development of new-onset diabetes 
occurred at a signiﬁ  cantly lower rate among bezaﬁ  brate 
allocated patients as compared with placebo (Figure 5). 
The mean time until onset of new diabetes was signiﬁ  cantly 
delayed among the former subgroup as compared with the lat-
ter: 4.6 ± 2.3 versus 3.8 ± 2.6 years, respectively, (p = 0.004), 
and bezaﬁ  brate therapy was shown to be associated with 
a signiﬁ  cant 30% reduction in the risk of new diabetes 
development. These ﬁ  ndings suggest that treatment with 
ﬁ  brates may reduce the incidence and delay the onset of type 
2 diabetes in patients with impaired fasting glucose, and need 
to be validated in future prospective studies.
Conclusions and future perspectives
With the epidemic proportions of obesity, especially high-
risk abdominal obesity, type 2 diabetes and the metabolic 
syndrome, it is important to consider lipid lowering therapies 
that affect the dyslipidemic proﬁ  le found in these patients, 
independently of LDL-C. Data from recent major clinical 
trials have shown that ﬁ  brates produce beneﬁ  cial effects 
on atherogenic lipoproteins through activation of PPARα, 
and confer long-term cardiovascular protection, both in the 
primary- and secondary- prevention setting. Therefore, this 
mode of lipid-lowering therapy should be considered part of 
an optimal management plan in a signiﬁ  cant proportion of 
patients with a high-risk metabolic proﬁ  le.
Recent data from the BIP trial have demonstrated several 
important ﬁ  ndings regarding the beneﬁ  t of this ﬁ  bric acid 
derivative in CHD patients, including (1) long-term cardio-
protective effects that extend beyond the period of active 
drug therapy; (2) enhanced efﬁ  cacy in “responders” (patients 
in whom HDL-C levels increase in response to bezaﬁ  brate 
therapy; (3) enhanced efﬁ  cacy in patients with elevated 
triglycerides and those with clinical and laboratory features 
suggestive of the metabolic syndrome; and (4) a signiﬁ  cant 
reduction in the incidence of new onset of type 2 diabetes in 
patients with impaired fasting glucose.Vascular Health and Risk Management 2008:4(1) 140
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Further studies are needed to compare the beneﬁ  t of statin 
versus ﬁ  brate therapy, or the combination of both classes of 
drugs, in different subpopulations of patients with a high-risk 
metabolic proﬁ  le.
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